IMMUCELL CORP. news, videos and press releases
For more news please use our advanced search feature.
IMMUCELL CORP. - More news...
IMMUCELL CORP. - More news...
- ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024
- ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®
- ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
- ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023
- ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023
- ImmuCell Announces Submission of CMC Technical Section to the FDA
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023
- ImmuCell Announces Change in Timing of Anticipated FDA Submission
- ImmuCell Appoints Bryan K. Gathagan to Board of Directors
- ImmuCell Announces Approval of Principal Terms of a $3 Million Debt Facility
- ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023
